Ozempic could be the next target of Medicare drug price negotiations – here's why

Wall Street analysts expect Ozempic to be selected for price negotiations in 2025 due to the amount of money Medicare Part D already spends on the drug.

from Health and Science https://ift.tt/93zXYZ0
https://ift.tt/wTJjS5D
https://ift.tt/OqxLouF